**ORIGINAL ARTICLE**

Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator

SMW Loya¹,² and X Zhang¹

Although oncolytic viruses have shown great promise as cancer therapeutics, results from a recent phase III clinical trial indicate that their potency may need further improvement for a clear clinical benefit. Here, we report a novel strategy to increase the bystander effect of virotherapy by arming an oncolytic virus with a secreted form of a Her2 single chain antibody linked to a self-multimerizing Fas ligand extracellular domain (Her2-COL-sFasL). The rationale is that, due to its much smaller size, this apoptosis activator can overcome obstacles such as the dense collagen in the tumor tissues to spread more freely than the viral particles. When measured in vitro, Her2-COL-sFasL was found to efficiently induce caspase cleavage, resulting in an 80% reduction in cell viability. Once incorporated into the genome of an oncolytic type 2 herpes simplex virus, FusOn-H3, Her2-COL-sFasL potentiates the therapeutic efficacy of the virus in an aggressive syngeneic mammary tumor model. Our data suggest that arming an oncolytic virus with a secretable and self-multimerizing apoptosis inducer is a feasible strategy to improve the potency of virotherapy.

INTRODUCTION

Despite the steady progress made in recent years to improve standard of care, many patients with malignant diseases nevertheless receive poor prognoses. Consequently, the urgent development of new therapies is critical. Cancer virotherapy specifically represents one of the new attempts. Unlike other biotherapeutics currently under research and development, virotherapy has a simple yet pragmatic antitumor mechanism—harnessing the intrinsic cytolytic capability of a virus for targeted killing of cancer cells. Many viruses have been modified for oncolytic purpose, including a type 2 herpes simplex virus (HSV-2) that we have used for the construction of FusOn-H2 that can selectively replicate in tumor cells with an activated Ras signaling pathway.¹ In recent years, several oncolytic viruses have been evaluated in clinical trials for treatment of a variety of malignant diseases. However, despite these exciting developments, the clinical outcome from a recent phase III clinical trial indicates that the therapeutic efficacy of current versions of oncolytic viruses needs to be further improved before their full clinical benefit may be realized.

Arming an oncolytic virus with a molecule that can incite an additional killing effect against tumor cells is an appealing strategy to potentiate virotherapy. Indeed, it has been reported that incorporation of molecules, such as the prodrug converting enzyme thymidine kinase and fusogenic glycoproteins that can arm the virus with a secretable apoptosis activator can overcome obstacles such as the dense collagen in the tumor tissues to spread more freely than the viral particles. Although oncolytic viruses have shown great promise as cancer therapeutics, results from a recent phase III clinical trial indicate that their potency may need further improvement for a clear clinical benefit. Here, we report a novel strategy to increase the bystander effect of virotherapy by arming an oncolytic virus with a secreted form of a Her2 single chain antibody linked to a self-multimerizing Fas ligand extracellular domain (Her2-COL-sFasL). The rationale is that, due to its much smaller size, this apoptosis activator can overcome obstacles such as the dense collagen in the tumor tissues to spread more freely than the viral particles. When measured in vitro, Her2-COL-sFasL was found to efficiently induce caspase cleavage, resulting in an 80% reduction in cell viability. Once incorporated into the genome of an oncolytic type 2 herpes simplex virus, FusOn-H3, Her2-COL-sFasL potentiates the therapeutic efficacy of the virus in an aggressive syngeneic mammary tumor model. Our data suggest that arming an oncolytic virus with a secretable and self-multimerizing apoptosis inducer is a feasible strategy to improve the potency of virotherapy.

The extrinsic pathway of apoptosis is a well-characterized pathway to activate programmed cell death via a cell surface interaction. This form of programmed cell death is activated following the binding of a transmembrane ligand located on the cell membrane with its respective transmembrane death receptor located on the surface of a target cell. Two commonly studied transmembrane ligands that activate the extrinsic pathway of apoptosis are the TNF-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL). TRAIL binds to death receptor 4 (DR4) and DR5, while FasL (also known as CD95 ligand) binds to the Fas receptor (CD95). Binding of TRAIL or FasL to their respective receptors leads to signaling inside the cell through formation of an intracellular death-inducing signaling complex at the cytoplasmic domain of the receptors.⁸ Death-inducing signaling complex formation results in proteolytic processing of initiator caspase-8. Caspase-8 then activates executioner caspase-3 and -7 that then process various proteins responsible for apoptosis.¹⁰

TRAIL has been shown to induce apoptosis in a variety of cancer cells without harming normal cells and accordingly active forms of recombinant TRAIL can be safely systemically administered.¹¹,¹² Multiple TRAIL-based cancer therapeutics have been developed and moved into phase I clinical trials. However, the clinical outcomes suggest translation of the tumor killing properties of TRAIL as a single agent has not proven successful.¹³–¹⁵ Due to the safety profile of TRAIL-based therapies, multiple investigators have effectively established oncolytic viruses that safely deliver
transmembrane or soluble TRAIL transgenes for the treatment of multiple cancer subtypes in vitro and in vivo. The more important ligand for our study is FasL, in which its proteolytic cleavage produces a soluble form consisting of the FasL extracellular domain that has 1000-fold less apoptosis-inducing capacity. The apoptosis signaling activity of this soluble form of FasL can be restored through forced multimerization or secondary crosslinking. Unlike TRAIL, however, FasL lacks tumor selective properties and therefore intravenous injection of active molecules targeting the Fas receptor results in rapid systemic toxicity. As such, safe viral delivery of FasL requires strict control of gene expression but has identified FasL as a potent anticancer agent. Yet, due to safety concerns, the use of active soluble FasL (sFasL) molecules as cancer therapeutics has not been widely explored. We examined the possibility of potentiating FusOn-H3 with a soluble form of either TRAIL or FasL. When we compared their potency, we found that FasL was significantly more effective than TRAIL at inducing apoptotic death of several tumor cells that we tested. We thus focused on a self-multimerizing form of sFasL and used two strategies to limit its effect to tumor cells. First, we linked this multimerized sFasL to a single chain antibody specific for the tumor antigen Her2. We then inserted it into the backbone of FusOn-H3, so that it is expressed in the context of a conditionally replicating oncolytic virus. This will safely establish a high relative concentration of this secreted multimerized sFasL specifically at the tumor site. As a result, secreted molecules will induce apoptotic death of bystander uninfected tumor cells, inciting a maximal therapeutic effect of both the oncolytic virus and the chimeric sFasL molecule.

RESULTS

Construction of secreted sFasL chimeric molecules that can self-multimerize as active apoptosis activators

We first designed and constructed a panel of chimeric molecules with differing combinations of functional domains. A schematic of the constructs is shown in Figure 1a. First, an optimal secretion signal and hemagglutinin (HA) tag was fused to the amino-terminus of sFasL (amino acids 139–281 of the extracellular domain) forming Secr-sFasL. Second, for the purpose of multimerization, a previously optimized collagen-based multimerization domain (COL) was inserted between the HA tag and sFasL domain, forming COL-sFasL. The COL domain consists of the hinge region of human IgG at the N terminus, a collagen-like scaffold (glycine-proline-proline)10 repeat flanked at the C terminus by the NC1 domain of type XXI collagen (see Supplementary Figure S1 for sequence details). Furthermore, Her2-COL-sFasL was constructed by inserting the Her2 scFv between the secretion signal and HA tag of COL-sFasL. For comparison, Her2-sFasL was constructed by inserting the Her2 scFv between the secretion signal and HA tag of Secr-sFasL. In addition two control constructs, HA-COL and Her2-COL, were made that contain differing functional domains without sFasL.

To verify secretion and to characterize multimerization of the chimeric molecules, HCT116 cells were transfected with the indicated constructs and 48 h later the transfected cell media was collected for western blot analysis. HCT116 cells were primarily chosen for this and subsequent experiments for their high sensitivity to FasL, Her2 expression on their cell surface and permissiveness to FusOn-H3 replication (data not shown). All the chimeric molecules are produced and secreted by the transfected cells at their respective predicted molecular weights (Supplementary Table S1), with the relative secretion levels varying between the chimeric proteins (Figure 1b). Although Her2-sFasL and Her2-COL-sFasL molecules appear to be produced the least, we cannot completely rule out the possibility that this variation may be due to the HA tag placement (in the middle of these two chimeric molecules) that may affect the binding affinity of the anti-HA antibody. As predicted, under non-reducing conditions the chimeric molecules that contain the COL domain (HA-COL, Her2-COL, COL-sFasL and Her2-COL-sFasL) are multimerized into trimeric structures whereas Secr-sFasL and Her2-sFasL are not (Figure 1c). It is also noticed that, although most of the COL domain-containing molecules multimerize into trimers, disulfide bond formation at the NC1 domain between two trimers allows hexamer formation as seen by the higher molecular weight band in COL-sFasL (Figure 1c). Thus, the chimeric molecules are expressed, multimerized and secreted at a readily detectable level into the transfected cell media.

The multimerized forms of sFasL-containing chimeric molecules can induce caspase activation and cell death

Caspase-8 is an initiator caspase specific to the extrinsic pathway, whereas caspase-3 is an executioner caspase that activates the downstream events resulting in cell death through apoptosis. Therefore, we tested the ability of the secreted molecules to induce caspase cleavage to activate apoptosis by measuring the cleavage of caspase-8 and caspase-3 into their respective active cleaved forms (p18 and p19, respectively). An equal volume of the 48 h HCT116 cell media used for Figures 1b and c was added to freshly seeded HCT116 cells, which were then incubated for 24 h. Afterwards, cells were collected and samples with equal amounts of protein were loaded for western blot analysis. HCT116 cells treated with media containing control sFasL molecules that lack a multimerization domain or control molecules lacking the sFasL domain show negligible caspase-8 or caspase-3 cleavage (Figure 2a). Whereas, the transfer of media containing Her2-sFasL, COL-sFasL or Her2-COL-sFasL to HCT116 cells led to significant cleavage of caspase-8 and caspase-3 into their respective active products. These results thus indicate that the ability of these sFasL-containing chimeric molecules to self-multimerize into an active form is crucial for them to activate caspase cleavage.

Next, we examined whether the induced caspase cleavage by these three molecules affected cell viability. Supernatants were collected the same way as in Figure 2a and subsequently added to freshly seeded HCT116 cells in triplicate, which were then incubated for 48 h. Afterwards, cell viability was determined by trypan blue exclusion assay and the obtained results were normalized to the GFP-transfected cell media treated cell control. The result shows that all three molecules shown to activate caspase cleavage also can significantly reduce the amount of viable HCT116 cells (Figure 2b). However, the most potent one among the three active molecules is Her2-COL-sFasL. It reduces the amount of viable cells to a very low level, at 21% of the control. These results, together with those shown in Figure 2a, indicate that, in addition to the ability to multimerize, the addition of the Her2 scFv to the chimeric molecule also potentiates its ability to induce apoptosis.

Considering the chimeric molecules were secreted at different quantities in the supernatants (Figures 1b and c), we then conducted a supernatant transfer experiment in which two of the most potent molecules, COL-sFasL and Her2-COL-sFasL, were adjusted to an equal amount (Supplementary Figure S2). With the adjusted quantity, Her2-COL-sFasL still showed a similar potency in decreasing the cell viability (to 22%), while a minimal decrease in percent viable cells (to 88%) is seen with an equivalent amount of COL-sFasL (Figure 2c). This result indicates that Her2-COL-sFasL is intrinsically more potent than the other chimeric molecules in inducing tumor cell death. As such, it was chosen as the prototype for insertion into the oncolytic virus for further examination. Three other molecules, Her2-COL, Her2-sFasL and COL-sFasL, were also inserted into the virus as controls for the purpose of comparison.
Figure 1. Design and western blot analysis of secreted multimerized sFasL chimeric molecules. (a) Schematic representation of the sFasL chimeric molecules used in this study. A portion of the FasL extracellular domain (amino acids 139–281) was used to make constructs. Secr, optimal secretion signal; HA, hemagglutinin tag; COL, collagen-like trimerization domain; Her2 scFv, FRP5 Her2 single chain variable fragment; TM, transmembrane domain; AA, amino acids. (b, c) Western blot detection of secreted chimeric sFasL molecules under reducing and non-reducing conditions. HCT116 cells were transfected with mammalian expression constructs encoding the respective chimeric molecules. After 48 h, cell debris was removed from media and equal amounts of media subjected to western blot analysis (b) with 25 mM DTT and (c) without DTT. HA tag antibody was used for detection and data shown at two different exposure times for clarity. Western blot results are representative of three independent experiments.
Construction and verification of recombinant oncolytic viruses that contain apoptosis-inducing chimeric molecules

The parental virus used throughout these experiments as the backbone for all recombinant viruses is FusOn-H3. FusOn-H3 is derived from a previously reported HSV-2-based oncolytic virus, FusOn-H2,1 by removing the GFP gene contained in the parental virus (Supplementary Figure S3). Initially, the gene encoding red fluorescent protein (RFP) flanked by two Cre recombinase recognition sequences that cannot cross-interact (loxP and lox2272) was inserted into a locus adjacent to the modified ICP10 gene cassette in the genome of FusOn-H3 through homologous recombination (Supplementary Figure S3). As depicted in Figure 3a, the new virus is designated as FusOn-H3-RFP. For further virus construction, recombinase-mediated cassette exchange was used to rapidly produce recombinant viruses.30 In the presence of Cre recombinase and a molar excess of the donor plasmid containing the desired insert flanked by the two sites as described in Figure 3b, the insert is rapidly and specifically exchanged into the viral backbone at the location of the corresponding recognition sites. Therefore, co-transfection of linear donor plasmid (inserts shown in Figure 3b) with purified FusOn-H3-RFP DNA into a Cre-overexpressing Vero cell line results in rapid production of recombinant viruses.

Using this strategy, viruses expressing Her2-COL, Her2-sFasL, COL-sFasL and Her2-COL-sFasL were constructed using the donor plasmids shown in Figure 3b, creating FusOn-H3-Her2-COL, FusOn-H3-Her2-sFasL, FusOn-H3-COL-sFasL and FusOn-H3-Her2-COL-sFasL recombinant oncolytic viruses, respectively. Upon plaque formation, recombinants were easily identified through a change in fluorescence marker from RFP to GFP. The recombinant viruses were subsequently purified to homogeneity by multiple rounds of plaque purification in Vero cells. PCR amplification of

Figure 2. Chimeric sFasL molecules induce caspase activation and cell death in vitro. HCT116 cells were transfected with respective molecules. Media was collected after 48 h and cellular debris removed. (a) Caspase-8 and -3 cleavage following treatment with chimeric sFasL molecules. Western blot analysis of equal amounts of HCT116 cellular protein after 24 h of specified media treatment. Caspase-8 and caspase-3 antibodies were used to detect active cleavage products specified (p18 and p19, respectively). GAPDH was used as a loading control. In (b, c) viable HCT116 cells counted using trypan blue exclusion assay 48 h after specified media treatment. Then triplicate values were averaged and percent viable cells calculated by normalization to GFP control media treated cells. (b) Reduced HCT116 cell viability following supernatant transfer. Data shown are the average of three independent experiments; **P < 0.001 as compared with GFP transfected cell media treatment controls using Student’s T-test. (c) HCT116 cells treated in triplicate with equal amounts of COL-sFasL and Her2-COL-sFasL. Data are representative of two independent experiments. ns, not significant; **P < 0.001 using Student’s T-test. Graphs show mean ± s.e.m.
viral DNA purified from the recombinants was then used to further verify gene insertion at the correct locus (Supplementary Figures S4 and S5). Secretion of the molecules was verified by infecting HCT116 cells at a multiplicity of infection (MOI) of 1 for 24 h. An equal volume of media was used for western blot analysis under non-reducing conditions using the HA tag for detection (Figure 3c). Under non-reducing conditions, the molecules secreted following viral infection are also multimerized as seen in Figure 1c and described in Supplementary Table S1. Similar to what was seen in the transfected HCT116 cell media shown in Figure 1, the relative amount of molecules secreted following infection with the recombinant viruses is also not equivalent. These data demonstrate that these apoptosis-inducing chimeric molecules can be efficiently expressed from the oncolytic FusOn-H3 once the gene cassettes were inserted into the virus backbone.

Arming FusOn-H3 with apoptosis activators increases caspase activation in infected cells while not severely inhibiting virus replication

To determine whether the sFasL-containing chimeric molecules expressed by the recombinant viruses could induce apoptosis activation, HCT116 cells were infected with the viruses at an MOI of 0.1 for 30 h. Several viruses, including the HSV-1-based oncolytic virus Baco-1, wild-type HSV-2 (wt186) and the parental FusOn-H3 were included as controls. Cells were then harvested and caspase-8 and -3 cleavage was examined. The results in Figure 4a show that, unlike Baco-1 or wt186, FusOn-H3 induced a measurable level of caspase-8 cleavage. This result supports our previous finding that the deletion introduced into the N-terminal region of the ICP10 gene in FusOn-H2 increased the ability of the virus to induce apoptotic death of the infected cells. However, both FusOn-H3-COL-sFasL and FusOn-H3-Her2-COL-sFasL induced a higher level of caspase-8 cleavage than FusOn-H3. Moreover, both FusOn-H3-COL-sFasL and FusOn-H3-Her2-COL-sFasL induced noticeable caspase-3 cleavage while no caspase-3 cleavage was visible in samples harvested from cells infected with FusOn-H3 (Figure 4a). Similar to the findings from supernatant transfer, FusOn-H3-Her2-COL-sFasL is particularly potent at inducing cleavage of both caspase-8 and -3. In contrast, FusOn-H3-Her2-sFasL, which contains the non-trimerized Her2-sFasL molecule, did not significantly increase the cleavage of either caspase. This further reinforces the importance of...
multimerization in the ability of these sFasL-containing molecules to induce apoptosis.

Next we examined whether the addition of these molecules to the oncolytic virus affects viral replication. HCT116 cells were infected with the recombinant viruses at an MOI of 1 for 24 or 48 h followed by subsequent virus titration in Vero cells. As shown in Figure 4b, all the recombinant viruses had lower virus yield as compared with the parental FusOn-H3 at both time points, indicating that insertion of the gene cassettes containing these chimeric molecules affects virus replication to a certain degree. The results also showed a tendency of inverse correlation between the ability of the molecules to induce caspase cleavage and the virus yield in the tumor cells, indicating that the impact of the molecules on the tumor cells also affects virus replication. Overall these results demonstrate that infection with FusOn-H3-Her2-COL-sFasL results in the highest level of apoptosis activation without abolishing virus replication.

Arming of FusOn-H3 with Her2-COL-sFasL can enhance and extend the therapeutic effect of the oncolytic virus in vivo.

For initial in vivo studies, we chose the FusOn-H3-Her2-COL-sFasL recombinant virus that contains the most active apoptosis-inducing activator. We initially compared FusOn-H3-Her2-COL-sFasL with the parental FusOn-H3 for their therapeutic effect against HCT116 xenograft tumors established subcutaneously in NSG mice. When HCT116 tumors reached the approximate diameter of 5 mm, mice were randomly separated into three treatment groups as follows: PBS control group, FusOn-H3 and FusOn-H3-Her2-COL-sFasL. The viruses were intratumorally injected at a relatively low dose of \(1 \times 10^5\) plaque forming units (p.f.u.) to allow the additional antitumor effect from the transgene to be fully displayed. Tumors were measured twice a week following treatment and the results are shown in Figure 5. At this relatively low dose, FusOn-H3-Her2-COL-sFasL almost completely halted tumor growth throughout the length of the experiment. Although the tumors treated with the parental FusOn-H3 virus are much smaller than those in the PBS control group, these tumors steadily increased in size following virotherapy (Figure 5). Consequently, these results strongly suggest that incorporation of Her2-COL-sFasL can potentiate the therapeutic effect of the backbone oncolytic virus.

FusOn-H3-Her2-COL-sFasL retrieved from in vivo passage in tumor-bearing mice maintains high titer and shows enhanced efficacy against a syngeneic murine tumor.

The results in Figure 4b showed that incorporation of Her2-COL-sFasL into the FusOn-H3 backbone affected the virus replication by almost a
indicating the strategy to improve virus replication through passage also applies to this sFasL-containing oncolytic HSV. 

closer to the level of FusOn-H3 parental virus (herein referred to as FusOn-H3-Her2-COL-sFasL*) replicates other viruses in inducing caspase cleavage (Figure 4a). (FusOn-H3-Her2-COL-sFasL) is also the most effective among genome of FusOn-H3, the Her2-COL-sFasL-containing virus killing of tumor cells (Figures 2b and c). When inserted into the model, the second dose of either virotherapy initially shrinks the tumor size. However, then the armed virus arrests the tumor growth for an extended period of time, while tumors treated with FusOn-H3-Her2-COL-sFasL* are more effective than the parental FusOn-H3-Her2-COL-sFasL. The tumors were intratumorally injected twice, on day 0 and day 7, using a relatively high dose of 1 × 10^7 p.f.u., as these murine tumor cells are only semi-permissive to the viruses. Tumors were then measured twice weekly and the results are shown in Figure 6b. FusOn-H3-Her2-COL-sFasL* is able to successfully prolong 4T1 tumor regression until the end of the experiment including one tumor-free mouse by day 15. In contrast, the therapeutic effect from the parental FusOn-H3 virus diminished after day 15 in which tumors begin to regrow. Taken together, these results demonstrate that secretion of Her2-COL-sFasL by an in vivo passaged oncolytic virus safely intensifies the therapeutic efficacy of the parental oncolytic virus in a syngeneic model of breast cancer.

DISCUSSION

Interest in oncolytic virotherapy has gained considerable popularity in recent years, and there is an increasing chance that it may become an invaluable cancer therapeutic. However, recent phase III clinical trial results suggest that further improvement on its potency is necessary before this may become a reality. To date, multiple strategies have been applied to enhance the potency of oncolytic viruses. However, most of these strategies have been designed in such that they act on the same tumor cells the virus infects. As such, there is limited gain through an additional bystander effect. In this study, we designed a novel strategy to arm an HSV-2-based oncolytic virus with a multimerized secreted FasL molecule that acts externally. Owing to the relatively small size, this molecule would be able to diffuse freely throughout the tumor tissues as an active form following production by infected tumor cells, inciting an additional bystander effect. Our in vitro data showed that FasL molecules that could self-multimerize, but not those that do not contain the multimerization domain, can effectively induce caspase activation (Figure 2a). And this resulted in efficient killing of tumor cells (Figures 2b and c). When inserted into the genome of FusOn-H3, the Her2-COL-sFasL-containing virus (FusOn-H3-Her2-COL-sFasL) is also the most effective among other viruses in inducing caspase cleavage (Figure 4a). In vivo evaluation suggests that FusOn-H3-Her2-COL-sFasL and FusOn-H3-Her2-COL-sFasL* are more effective than the parental FusOn-H3 in treating both xenograft and syngeneic tumors. In the xenograft tumor model, the armed virus almost completely halted tumor growth when given as a relatively low dose, while the tumors treated with the parental virus progressively increased in size. In the syngeneic murine mammary tumor model, the second dose of either virotherapy initially shrinks the tumor size. However, then the armed virus arrests the tumor growth for an extended period of time, while tumors treated with FusOn-H3 begin to rapidly regrow. Together, these results demonstrate that arming oncolytic viruses with secretable FasL extrinsic apoptosis activators is a promising strategy to potentiate virotherapy by producing a better and more sustained antitumor effect than the unarmed virus.
It has been described in the literature that linking a scFv to sTRAIL or sFasL can increase target antigen-specific bioactivity. Consistent with these reports, incorporation of the Her2 scFv alone to sFasL enhanced its killing effect on Her2-positive colon carcinoma cells but not the Her2-negative 4T1 cells (Supplementary Figure S6). On the contrary, the potentiating effect from the combined addition of both a scFv and a multimerization domain seems to be more diverse. Trebing et al. show that addition of both a multimerization domain and scFv to sTRAIL enhances its potency on cells expressing the surface target antigen, but the molecule also maintains activity on target antigen-negative cells. Consistent with their findings, we noticed that Her2-COL-sFasL, which contains both a Her2 scFv and a COL multimerization domain, has enhanced in vitro cell killing in both Her2-positive HCT116 cells (Figure 2b) and Her2-negative 4T1 cells (Supplementary Figure S6) in contrast to molecules with either single domain. We speculate that the Her2 scFv may increase the potency of COL-sFasL either by efficiently immobilizing it to the cell surface or by structural stabilization of the chimeric molecule itself. Regardless of its mechanism, our data clearly demonstrate that the Her2 scFv can further potentiate the killing effect of the multimerized sFasL chimeric molecules.

Insertion of the sFasL-containing chimeric molecules into the viral genome seems to affect virus yield. Although there was no problem attaining the recombinant viruses, there is a nearly a log decrease in the titer of FusOn-H3-Her2-COL-sFasL as compared with the parental FusOn-H3-Her2 (Figure 4c). Despite this reduced virus yield, our in vivo data suggest this replication deficit seen in vitro does not prevent a visible in vivo therapeutic enhancement in the HCT116 model (Figure 5). Our data subsequently show that the reduced virus yield could be fully restored by a single round of in vivo passaging of FusOn-H3-Her2-COL-sFasL. The retrieved virus maintains the ability to produce functional transgene (data not shown) and when evaluated in a syngeneic tumor model, demonstrates a superior therapeutic efficacy over FusOn-H3 (Figure 6b). Previous studies by other researchers have shown that in vivo passage of oncolytic HSVs can improve virus replication in less permissive tumor cells. The reason why FusOn-H3-Her2-COL-sFasL, after being passaged once through the permissive HCT116 tumor, becomes more effective at replicating in less permissive tumor cells such as 4T1 is not clear. The Her2-COL-sFasL transgene is an unlikely contribution factor for this, as FusOn-H3 obtained from an HCT116 tumor from the same experiment also shows a fourfold increase in virus titer than the unpassaged virus (data not shown). One plausible explanation is that, due to the lack of selection pressure from permissiveness, ‘fitter’ viruses have been selected during this in vivo passage.

Multiple investigators have shown that oncolytic viruses can be safely armed with other apoptosis activators such as transmembrane or soluble TRAIL for the treatment of multiple cancer types. To date, oncolytic virus delivery of sFasL and especially sFasL molecules has not been as widely explored due to safety concerns. The few reports of arming other oncolytic virus platforms with FasL only describe the use of the transmembrane form. Although Chong et al. designed a bystander death-mediated transmembrane FasL, we chose a secreted form of FasL to maximize the bystander effect. To ensure safety, we chose to specifically deliver the secretable FasL molecule to tumor cells using our well-characterized HSV-2 oncolytic virus so that the molecule may only be expressed in the local tumor tissue. However, one concern is that the promoter that drives Her2-COL-sFasL expression, RSVLTR, is a constitutive promoter. This can potentially lead to the transgene expression in normal cells and hence unwanted toxicity. Nevertheless, both FusOn-H3-Her2-COL-sFasL and FusOn-H3-Her2-COL-sFasL seem to be well tolerated by the treated animals even when administered twice at a high titer (1 × 10⁷ p.f.u.) for the treatment of the 4T1 tumors. This is probably because the activity of a constitutive promoter in the context of an oncolytic virus will still be dictated by the ability of the virus to replicate. In normal cells where the virus cannot replicate, there is most likely only one copy of the virus genome (hence one copy of the transgene) per cell. As the virus will not be able to spread in normal tissues either, the number of virus infected cells in a given organ tissue is very limited and hence the amount of transgene expression. But in tumor cells where the virus can replicate, the virus genome (and hence the transgene) can be replicated hundreds of times within a 24 h period after infection. Additionally, the replicated virus can spread to the surrounding tumor cells. As such, the difference of transgene expression between tumor and normal tissues can be enormous. Taking these considerations together, we believe that delivery of Her2-COL-sFasL by the oncolytic virus in vivo is a safe and well tolerated strategy with no apparent visible illness or treatment-limiting side effects. Therefore, although Fas receptor-activating therapies are typically considered as unsafe for systemic administration, this study should encourage more work on establishing new treatment strategies aimed at harnessing the potent effects of soluble forms of FasL as cancer therapeutics using specific delivery methods such as the oncolytic virus described here.

**MATERIALS AND METHODS**

**Cell culture**

HCT116 (human colorectal carcinoma). Jurkat (immortalized T lymphocytes) and 4T1 (a mouse mammary adenocarcinoma) cells were obtained from the American Type Culture Collection (Manassas, VA, USA). 4T1 cells were kindly provided by Dr Fred Miller (Wayne State University, Detroit, MI). CreGH cell line was previously established in our laboratory as a Cre recombinase-overexpressing Vero cell line. HCT116, Vero, 4T1 and CreGH cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin unless specified during experiments. Jurkat cells were maintained in RPMI supplemented with 10% FBS and 1% penicillin-streptomycin.

**Cloning of sFasL molecules**

The chimeric fusion constructs were cloned using Phusion (NEB, Ipswich, MA, USA) for PCR of the specific domains with primers containing restriction sites followed by subsequent digestion and ligation into the pcDNA3.1 mammalian expression vector (Invitrogen, Grand Island, NY, USA). The optimal secretion signal used in all constructs encodes amino acids: MWWRLWLLLLLLLLWPMVWA. The HA tag was inserted via in-frame ligation of annealed oligos encoding the HA tag protein sequence (YPYDVPDYA). The Her2 scFv used is the FRP5 clone. The human codon optimized COL domain was synthesized by DNA2.0 (Menlo Park, CA, USA). For cloning of the full-length human FasL gene (BC017502.1), first RNA was extracted from stimulated Jurkat cells (50 ng ml⁻¹ phorbol myristate acetate and 1 μg ml⁻¹ ionomycin and 1 μM calcium) via TriReagent reagent (Invitrogen). The full-length human FasL cDNA was then amplified and the resulting PCR product sequenced. The sFasL domain fused into the constructs consists of the FasL DNA encoding amino acids 139–281 of the extracellular domain. Following cloning, all chimeric sFasL constructs were verified by sequencing.

**Viruses and virus purification**

Baco-1 (ref. 31) and wild-type HSV-2 (wt186) were previously described. FusOn-H3 virus used as the base for all recombinant viruses described was derived from FusOn-H2 (ref. 1) through homologous recombination. The resulting FusOn-H3 virus has the GFP portion of the GFP-ICP10 ribonucleotide reductase domain coding sequence replaced with a short in-frame linker. Thus, the linker-ICP10 ribonucleotide reductase domain is still driven by the CMV promoter but now lacks a fluorescent marker.

To establish the recombinase mediated cassette exchange system in the FusOn-H3 backbone non-interacting Cre binding sites, loxP and lox2272 were inserted into FusOn-H3 adjacent to the modified ICP10 loci. Between the loxP and lox2272 sites, an RFP expression cassette was inserted as a negative fluorescence marker for recombinants. The lox2272-RFP-loxP fragment was initially inserted into a plasmid containing the respective homologous regions (~1000 bases each) upstream and downstream from the desired insertion site. When linear plasmid is
co-transfected into Vero cells with FusOn-H3 viral DNA, homologous recombination occurs at the specified location in the viral DNA to produce the FusOn-H3-RFP virus described.

Donor plasmids for recombine-mediated cassette exchange were constructed in the PCR2.1 backbone (Invitrogen) by the insertion of two expression cassettes: one encoding the GFP fluorescent marker and the other encoding the target molecule. 4.10 transformants were screened, and plasmids werelinearized using SacI (NEB) followed by PCR purification (QIAGEN, Valencia, CA, USA). Purified FusOn-H3-RFP viral DNA was co-transfected with the linear donor plasmids at a ratio of 1:10 (viral:donor plasmid) into the CreGH cells using FuGENE HD (Promega, Madison, WI, USA). At 48 h post transfection, GFP fluorescent plaques were collected and further passaged in Vero cells until virus could be amplified from a single plaque into a 96-well plate. Pure virus was amplified and recombine viral DNA purified. PCR was then performed using hot start tag polymerase (NEB) to ensure correct insertion location and verify chimeric molecule insertion.

All viruses were amplified in Vero cells. After the cytopathic effect, cells were scraped off dishes, washed, resuspended in PBS, subjected to three freeze/thaw cycles and cell debris clarified by brief centrifugation. The lysate was titrated in Vero cells and then stored at –80°C until use. For titrations, HCT116 or 4T1 cells were infected at an MOI of 1 or 10 respectively for 24 or 48 h in triplicate wells. Total virus was collected and then titrated on Vero cells covered with 1% carboxymethylcellulose. After 48 h, cells were stained with crystal violet, plaques were counted, triplicate results averaged and the results were expressed as log50. p.f.u. per ml.

Media transfer treatment and trypan blue exclusion assay

HCT116 cells were transfected using FuGENE HD (Promega) in half of suggested media volume per well in 5% PBS DMEM (resulting in 2× concentrated secreted proteins). Media was collected 48 h post transfection and clarified by brief centrifugation. Fresh HCT116 or 4T1 cells were seeded in a 96-well plate and triplicate wells treated with 100 μl of media from cells transfected with specified constructs. Forty-eight hours after treatment cells were washed, trypsinized and resuspended in DMEM containing 10% FBS. An equal volume of trypan blue staining dye (Cellgro, Manassas, VA) was added to samples and then viable cells counted on a hemocytometer. Blue non-viable cells were not counted. Each treatment was performed in triplicate and viable cell counts averaged. Percent viable cells were derived from dividing the average of each treatment group by the average GFP-transfected media treated control cell. Results are representative of three independent experiments.

For normalization of Her2-COL-sFasl and COL-sFasl molecule levels, differing dilutions of COL-sFasl cell media (from transfected HCT116 cells as described above) were diluted as follows: undiluted, 1:2, 1:5, 1:10 and 1:25 using media from GFP-transfected controls as the dilution media. An equal volume of each diluted sample was subjected to western blot analysis using HA tag antibody C29F4 primary antibody (Cell Signaling #3724, Danvers, MA, USA) and HRP-conjugated anti-rabbit secondary antibody (Cell Signaling). Imaged (National Institutes of Health, Bethesda, MD, USA) was used to measure and quantify which dilution had the closest density to the undiluted Her2-COL-sFasl sample. Data shown are from the 1:10 COL-sFasl dilution which is about 1.8× higher than Her2-COL-sFasl according to densitometric analysis. The treatments were performed in triplicate, percent viable cell counts quantified at 48 h post treatment and normalized to GFP-transfected media treated cells. Representative figure is shown for two independent experiments.

SDS-PAGE and western blot analysis

To analyze secretion of chimeric molecules from transfected HCT116 cells, HCT116 cells were transfected using FuGENE HD (Promega) in half of suggested media volume per well in 5% PBS DMEM (resulting in 2× concentrated secreted proteins) and media collected 48 h post transfection. To analyze chimeric molecule secretion following infection, HCT116 cells were infected at an MOI of 1 in half volume of media and media collected 24 h post infection. Media were centrifuged at low speed to remove cell debris and 40 μl of sample prepared in native Laemmli buffer ± 25 mM DTT for reducing and non-reducing conditions. Samples were then boiled at 95°C for 5 min and loaded on Biorad mini protein TGX precast 4–20% gradient SDS-polyacrylamide gels. Protein gels were transferred onto PVDF membranes (Bio-Rad, Hercules, CA, USA) for analyzing by western blot using HA tag primary antibody and HRP-conjugated anti-rabbit secondary antibody. Amersham ECL prime Western blot detection reagent (GE Healthcare, Pittsburgh, PA, USA) was used for detection.

For caspase cleavage analysis following supernatant transfer, HCT116 cells were treated with the transfected 48 h. HCT116 cell media for 24 h then were lysed in RIPA buffer, briefly sonicated at 10% amplitude for 10 s and protein concentration determined using Bradford reagent (Sigma, St Louis, MO, USA). For caspase activation following infection, HCT116 cells were infected at an MOI of 0.1 for 30 h and cells collected in RIPA buffer as described above. Both the caspase-3 and caspase-8 (IC12) antibodies are from Cell Signaling (#9662 and #9746) and detect full-length caspase and caspase cleavage products. Samples of 50 μg protein were prepared in 1× Laemmli buffer and procedure for western blot used as above. As a loading control, GAPDH ACR001PT (Acris, San Diego, CA, USA) mouse IgG1 antibody was used.

FusOn-H3-Her2-COL-sFasl in vivo passing and in vivo experiments

For in vivo experiments, recombinant viruses were purified from infected cell media using high-speed centrifugation followed by titration for further experimentation. Animal experiments were performed following the guidelines of the Institutional Animal Care and Use Committee (IACUC) at the University of Houston. FusOn-H3-Her2-COL-sFasl was collected following in vivo passing in NOD scid mice. NOD scid mice were purchased from Taconic (Hudson, NY, USA). Mice were injected with 2.5 × 106 HCT116 cells in the right flank. When tumors reached 5 mm they were injected with 1.0 × 107 p.f.u. FusOn-H3-Her2-COL-sFasl. Tissue at the tumor site was collected 30 days post virus injection and homogenized to release the virus. Virus was then passaged in Vero cells, collected and amplified. PCR was used to verify maintenance of cassette insertion and also Her2-COL-sFasl secretion was verified via western blot.

NOD.Cg-Fkrdc-r+I2rgtm1Wjl/SzJ (NSG) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and BALB/c mice were purchased from Taconic. For the establishment of subcutaneous tumors, HCT116 or 4T1 cells were trypsinized, washed, counted and resuspended in PBS. NSG and BALB/c mice were injected in the right flank with 100 μl each containing 2.5 × 106 HCT116 cells and 1 × 105 4T1 cells, respectively. HCT116 tumors were injected with virus 8 days post tumor cell implantation at an average tumor diameter of 5mm. 4T1 tumors were injected 6 days post tumor cell implantation at an average tumor diameter of 4 mm followed by a second virus injection 7 days after first virus injection with the same p.f.u. of respective virus. For the HCT116 model in NSG mice, FusOn-H3 and FusOn-H3-Her2-COL-sFasl virus stocks were diluted to 1.0 × 107 p.f.u. per ml in PBS and 100 μl intratumorally injected per mouse for 1.0 × 107 (n = 5 mice per group) treatments at day 0. For the 4T1 model in BALB/c mice, FusOn-H3 and FusOn-H3-Her2-COL-sFasl virus stocks were diluted to 6.67 × 105 p.f.u. per ml in PBS and 150 μl intratumorally injected per mouse for 1.0 × 105 p.f.u. treatments (n = 5 mice per group) at day 0 and day 7. PBS control injection volumes matched the specified volumes of virus injected.

Tumor measurements were made every 2–3 days with a caliper by measuring the tumor length and width. Tumor volume was determined using the formula (mm3) = (length (mm)) × (width (mm))^2 × 0.52. The change in tumor volume was then determined by dividing each tumor volume by the tumor volume on day 0 (tumor size when virotherapy first administered). Then the change in tumor volume was averaged for each group of mice and plotted as shown.

Statistical analysis

All quantitative data are reported as means with error bars representing standard error mean (s.e.m.). Student’s T-test was used with a P < 0.05 being considered as statistically significant throughout.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Xingping Fu, Liuhua Tao, Armando Rivera, Kim Anthony-Gonda and Jeffrey Spencer for the sharing of their expertise for a variety of techniques. Also, we further thank Armando Rivera, Kim Anthony-Gonda and Jeffrey Spencer for reading of the manuscript before submission. This work was supported by the National Cancer Institute grants R01CA106671 and R01CA132792 and also by a grant from the William and Ella Owens Medical Research Foundation (to X2).
Arming oncolytic HSV with an extrinsic apoptosis inducer
SMW Loya and X Zhang

REFERENCES
1 Fu X, Tao L, Cai R, Prigge J, Zhang X. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 2006; 13: 882–890.
2 Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410–413.
3 Bauzon M, Jin F, Kretschmer P, Hemmiston T. In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of CololAd1-based treatment of cancer. Gene Therapy 2009; 16: 1169–1174.
4 Fu X, Tao L, Jin A, Vile R, Brenner M, Zhang X et al. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus provides potent synergistic anti-tumor effect. Mol Ther 2003; 7: 748–754.
5 Ebert O, Shinizaki K, Kournioti C, Park MS, Garcia-Sastre A, Park MS et al. Synteta induction enhances the oncolytic potential of vesicular stomatitis virus in vitrotherapy for cancer. Cancer Res 2004; 64: 3265–3270.
6 Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Cofin RS et al. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006; 66: 4835–4842.
7 Guerdan S, Grasas D, Rojas JJ, Gros A, Vilardell F, Vile R et al. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Therapy 2012; 19: 1048–1057.
8 Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007; 67: 10664–10668.
9 Medema JP, Scaffo C, Kischkel FC, Shevchenko A, Mann K, Kramer PH et al. FLICE is activated by association with the CD95 death-signaling complex (DISC). EMBO J 1997; 16: 2794–2804.
10 Mizio M, Salvesen GS, Dixit VM. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem 1997; 272: 2952–2956.
11 Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 2009; 104: 155–162.
12 Walczak H, Miller RE, Ariai K, Gliniak B, Griffith TS, Kubin M et al. Tumoralisactivity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
13 Younes A, Vose JM, Zelenetz AD, Smith MR, Burtis HA, Ansell SM et al. Phase 1/2 trial of a phase matupatuminab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 2010; 103: 1783–1787.
14 Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS et al. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus provides potent synergistic anti-tumor effect. Mol Ther 2003; 7: 748–754.
15 Ebert O, Shinizaki K, Kournioti C, Park MS, Garcia-Sastre A, Park MS et al. Synteta induction enhances the oncolytic potential of vesicular stomatitis virus in vitrotherapy for cancer. Cancer Res 2004; 64: 3265–3270.
16 Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Cofin RS et al. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006; 66: 4835–4842.
17 Guedan S, Grasas D, Rojas JJ, Gros A, Vilardell F, Vile R et al. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Therapy 2012; 19: 1048–1057.
18 Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007; 67: 10664–10668.
19 Medema JP, Scaffo C, Kischkel FC, Shevchenko A, Mann K, Kramer PH et al. FLICE is activated by association with the CD95 death-signaling complex (DISC). EMBO J 1997; 16: 2794–2804.
20 Mizio M, Salvesen GS, Dixit VM. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem 1997; 272: 2952–2956.
21 Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 2009; 104: 155–162.
22 Walczak H, Miller RE, Ariai K, Gliniak B, Griffith TS, Kubin M et al. Tumoralisactivity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
23 Younes A, Vose JM, Zelenetz AD, Smith MR, Burtis HA, Ansell SM et al. Phase 1/2 trial of a phase matupatuminab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 2010; 103: 1783–1787.
24 Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual pro-apoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28: 2839–2846.
25 Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21: 376–381.
26 Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL et al. Multimechanism tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther 2013; 21: 68–77.
27 Zhou W, Zhu H, Chen W, Hu X, Pang X, Zhang J et al. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus. Cancer Gene Ther 2011; 18: 336–345.
28 Cao X, Yang M, Wei RC, Zeng Y, Gu JF, Huang WD et al. Targeting gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Therapy 2011; 18: 765–777.
29 Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205–1213.
30 Holler N, Tardivel A, Kovacssovics-Bankowsk M, Hertog S, Gaide O, Martinon F et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell 2003; 12: 1428–1440.
31 Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebalb W et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95SL. Cell Death Diff 2007; 14: 2021–2034.
32 Ogawasara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806–809.
33 Li Y, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007; 13: 5463–5473.
34 Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997; 94: 13862–13867.

Supplementary Information accompanies this paper on Gene Therapy website (http://www.nature.com/gt)

Gene Therapy (2015) 237 – 246
© 2015 Macmillan Publishers Limited